Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA

Like
Comment
Favorite

Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA

MT Newswires Live03-17

Simcere Pharmaceutical Group (HKG:2096) said its new drug application (NDA) for its anti-influenza drug was accepted by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.

The drug is developed in partnership with Jiaxing AnDiCon Biotech. A Single tablet of the drug known as Jiaxing AnDiCon Biotech stops the virus replication within 24 hours. The medication is also useful in children under 12, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

23:30
Jenscare Scientific - Ken-Valve Obtained Registration Approval From Nmpa China
23:27
Panama Government Says It Got a 1.2 Bln Euros Loan From Banco Santander - Statement
23:27
Ravelin Properties REIT Announces Changes to Board of Trustees
23:12
Australia's S&P/ASX 200 Index Rises 0.6% to 7,980.40 Points in Early Trade
23:06
LG Energy Solution: to Supply ESS to Poland's Pge of About 16 Gigawatts From 2026

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2520550487?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-17 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520550487","market":"nz","top_or_hot":-1,"title":"Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA","media":"MT Newswires Live","content":"<html><body><p> Simcere Pharmaceutical Group (HKG:2096) said its new drug application (NDA) for its anti-influenza drug was accepted by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.</p><p>The drug is developed in partnership with Jiaxing AnDiCon Biotech. A Single tablet of the drug known as Jiaxing AnDiCon Biotech stops the virus replication within 24 hours. The medication is also useful in children under 12, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-17 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Simcere Pharmaceutical Group (HKG:2096) said its new drug application (NDA) for its anti-influenza drug was accepted by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.</p><p>The drug is developed in partnership with Jiaxing AnDiCon Biotech. A Single tablet of the drug known as Jiaxing AnDiCon Biotech stops the virus replication within 24 hours. The medication is also useful in children under 12, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520550487","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520550487","pubTimestamp":1742186043,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Simcere Pharmaceutical Group  said its new drug application  for its anti-influenza drug was accepted by China's National Medical Products Administration , according to a Monday filing with the Hong Kong bourse.The drug is developed in partnership with Jiaxing AnDiCon Biotech. A Single tablet of the drug known as Jiaxing AnDiCon Biotech stops the virus replication within 24 hours. The medication is also useful in children under 12, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","02096":"先声药业"},"translate_title":"先声药业集团获NMPA抗流感NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9},"content_text":"Simcere Pharmaceutical Group (HKG:2096) said its new drug application (NDA) for its anti-influenza drug was accepted by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.The drug is developed in partnership with Jiaxing AnDiCon Biotech. A Single tablet of the drug known as Jiaxing AnDiCon Biotech stops the virus replication within 24 hours. The medication is also useful in children under 12, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}